鼻内接种流感病毒疫苗对抗致死性病毒攻击
研究在小鼠模型中评价CTA1-DD黏膜佐剂联合H1N1裂解疫苗经鼻内接种的效果。结果显示CTA1-DD佐剂疫苗提供100%死亡保护并大幅降低发病率,诱导的血清血凝抑制滴度和IgG抗体显著高于铝佐剂,并促进肺灌洗液和阴道灌洗液黏膜分泌型IgA产生及T细胞应答。
要点
- CTA1-DD佐剂疫苗在小鼠中提供100%死亡保护并大幅降低发病率。
- CTA1-DD诱导的血清血凝抑制滴度和IgG抗体显著高于铝佐剂。
- CTA1-DD促进肺灌洗液和阴道灌洗液黏膜分泌型IgA及T细胞应答。
核心结论
- CTA1-DD有助于激发有效流感疫苗接种所需的保护性细胞免疫应答,提示该佐剂可进一步探索作为呼吸系统疾病和其他黏膜疾病的临床安全黏膜疫苗佐剂。
研究设计与样本
- 在小鼠中经鼻内给予H1N1裂解疫苗联合CTA1-DD佐剂,并与铝佐剂比较。
主要发现
- CTA1-DD佐剂疫苗在小鼠模型中提供100%死亡保护并大幅降低发病率。
- 添加CTA1-DD至疫苗所诱导的血清血凝抑制滴度和IgG抗体显著高于铝佐剂。
- CTA1-DD显著促进肺灌洗液和阴道灌洗液中黏膜分泌型IgA的产生。
- CTA1-DD可作为黏膜佐剂增强T细胞应答。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Vaccine adjuvants are essential for enhancing immune responses during vaccination. However, only a limited number of safe and effective adjuvants, especially mucosal adjuvants, are available for use in vaccines. The development of a practically applicable mucosal adjuvant is therefore urgently needed. Here, we showed that the non-toxic CTA1-DD adjuvant, which combined the full enzymatic activity of the A1 subunit of cholera toxin (CT) with two immunoglobulin-binding domains of Staphylococcus aureus protein A (SpA), promoted mucosal and systemic humoral and cell-mediated immune responses following intranasal administration with H1N1 split vaccine in mice. We demonstrated that CTA1-DD-adjuvant vaccine provided 100% protection against mortality and greatly reduced morbidity in a mouse model. We also showed that addition of CTA1-DD to the vaccine elicited significantly higher hemagglutination inhibition titers and IgG antibodies in sera than alum adjuvant. Furthermore, CTA1-DD significantly promoted the production of mucosal secretory IgA in lung lavages and vaginal lavages. We also showed that CTA1-DD could be used as a mucosal adjuvant to enhance T cell responses. Our results clearly indicated that CTA1-DD contributed to the elicitation of a protective cell-mediated immune response required for efficacious vaccination against influenza virus, which suggested that this adjuvant could be explored further as a clinically safe mucosal vaccine adjuvant for respiratory diseases and other mucosal diseases.
引用
- Fan X, Su Q, Qiu F, et al. Intranasal inoculate of influenza virus vaccine against lethal virus challenge. Vaccine. 2018. PMID: 29880240. doi:10.1016/j.vaccine.2018.05.075
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。